Vaccine against Ebola: Commission grants first-ever market authorisation

ebola news.jpg

Finnish Red Cross/Maria Santto Rinsing Ebola protective gear in Beni, Democratic Republic of the Congo.

This article is brought to you in association with the European Commission.


Today, the European Commission adopted the decision granting marketing authorisation to the company Merck Sharp & Dohme B.V. for a vaccine against Ebola. This vaccine, called Ervebo, had been in development since the Ebola outbreak in West Africa in 2014. It is already used, as part of a specific protocol, to protect people at risk of infection, such as healthcare workers or people who have been exposed to infected persons.

This decision follows the recommendation from the European Medicines Agency (EMA), which has assessed the benefits and risks of the vaccine. It also follows the recent announcement of a clinical trial for a second Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) that is now under way in the Democratic Republic of Congo, with the support of the EU’s research and innovation programme Horizon 2020.

Vytenis Andriukaitis, Commissioner in charge of Health and Food Safety, said: “Finding a vaccine as soon as possible against this terrible virus has been a priority for the international community ever since Ebola hit West Africa five years ago. Today’s decision is therefore a major step forward in saving lives in Africa and beyond.”

Christos Stylianides, Commissioner for Humanitarian Aid and Crisis Management and EU Ebola Coordinator, said: “The EU is supporting international efforts to combat Ebola on all fronts, from vaccine development to delivering humanitarian aid on the ground. We will continue assisting the fight to tackle epidemic for as long as it takes.”

The clinical development of Ervebo was launched during the outbreak in West Africa five years ago. It was made possible through cooperation with public health stakeholders, which include national institutes of health, ministries of health in Africa (notably in Sierra Leone, Liberia, and Guinea), as well as the WHO, the Norwegian Institute of Public Health and Médecins Sans Frontières (MSF).

The development of the vaccine was supported by two projects from the Innovative Medicines Initiative (IMI) funded by the EU’s research and innovation programme Horizon 2020:

  • VSV-EBOVAC (March 2015-Feb. 2019), led by Academisch Ziekenhuis Leiden (NL) with €3.9 million EU contribution,
  • VSV-EBOPLUS (April 2016-March 2021), led by Merck Sharp & Dohme, with €8.5 million EU contribution.

Background

Ebola is a rare but severe illness caused by a virus of the same name. Death rates in patients who have contracted the disease have varied from 25% to 90% in past outbreaks. The largest outbreak to date occurred in West Africa in 2014-2016 with more than 11 000 deaths. The current outbreak in the Democratic Republic of Congo (DRC), caused by Ebola Zaire, has shown case fatality rates of approximately 67%. More than 3 000 people have been infected with the Ebola virus during the ongoing outbreak, which was declared a public health emergency of international concern by the World Health Organization (WHO) in July 2019. WHO extended this decision for another three months in October 2019.

The authorisation of a medicine under the centralised procedure is a two-stage process, involving the European Medicines Agency (EMA) and the European Commission.

EMA assesses the benefits and risks of medicines and makes recommendations to the Commission, which then takes a final legally binding decision on whether or not the medicine can be marketed in the EU.

This decision is issued normally within 67 days (legal deadline) of the scientific opinion of EMA (for Ervebo the date was 17 October). This phase includes, among other things, the translation of the product guidelines in all EU languages and a consultation with Member States (Comitology). In view of the public health interest, the Commission has accelerated this process and authorised the medicine in less than a month, in other words cutting the decision-making process in half.

The assessment report for Ervebo will be published on EMA’s website.

Moreover, the EU is part of the Innovative Medicines Initiative (IMI), a public-private partnership, which has supported the clinical development of the investigational preventive Ebola vaccines, as well as diagnostic tests through the IMI Ebola+ call.

Advertising

Advertising

Advertising

Advertising

Advertising

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Somalis ‘will not be deterred’ by Friday’s terror attacks – UN chief

The Catcher in the Rice

Heat stress spike predicted to cost global economy $2,400 billion a year

Brexit and migration dominates the debate on October’s EU summit

Plans to keep EU budget funding in 2020 in the event of a no-deal Brexit

EU car manufacturers worry about an FTA with Japan

Brexit: EP Group leaders support a flexible extension until 31/1/20

The Europeans with a job diminish dangerously

Turkey needs to step up investment in renewables to curb emissions

In Afghanistan, attacks against schools have tripled in one year

As human caravan moves through Mexico, ‘full respect’ needed for national control of borders: UN chief

Independent UN rights experts call for ‘immediate investigation’ into alleged Bezos phone hack by Saudi Arabia

Parliament makes it easier to organise a European Citizens’ Initiative

Young activists do the talking as UN marks World Children’s Day

What makes America the world’s most competitive economy?

4 things President Trump could learn from Jimmy Carter

Climate emergency: City mayors are ‘world’s first responders’, says UN chief

North Sea fisheries: MEPs back EU plan to sustain stocks of demersal species

Six months into DR Congo’s deadliest Ebola outbreak, top UN official praises ‘brave’ response effort

Global Citizen-Volunteer Internships

Wednesday’s Daily brief: Day 3 of anti-hatred summit, UNFPA turns 50, Ben Stiller #WithRefugees, updates on Abyei

Mankind’s first tool to fight malaria also kills

UN relief chief urges Security Council to back aid delivery, more funding for millions of Syrians hit by harsh weather

Mali facing ‘alarming’ rise in rights violations, warns UN expert

The future of manufacturing is smart, secure and stable

When is Berlin telling the truth about the EU banking union?

Wednesday’s Daily Brief: Guterres in Kenya, Prisoners sick in Iran, #GlobalGoals, Myanmar, Ukraine updates, and new space partnership

Don’t let smoking steal life’s breathtaking moments, urges UN health agency

Millions of Bangladeshi children at risk from climate crisis, warns UNICEF

Somalia: UN urges steps to ensure future elections not ‘marred’ by rights abuses seen in recent polls

THE ROAD TO GANESHA

Why income inequality is bad for the climate

OECD strengthens co-operation with Morocco – Renews Morocco Country Programme Agreement

How quantum computing could beat climate change

Why do medical students need to emigrate to become doctors in 2017?

Malaysia can show the way towards a holistic model for human rights

Eurozone: Retail sales and inflation point to recession

When it comes to envirotech adoption, NGOs can lead us out of the woods

Have we reached peak smartphone?

Africa: Urgent action needed to mobilise domestic resources as tax revenues plateau

Why do US presidential elections last so long? And 4 other things you need to know

We can save our ocean in three steps – if we act now

4 bold new ways New York is going clean and green

Denmark plans ‘Silicon Valley’ on 9 artificial islands off Copenhagen

Joint EU-U.S. statement following the EU-U.S. Justice and Home Affairs Ministerial Meeting

A win-win strategy for private equity deals

Humanitarian visas would reduce refugees’ death toll

5 libraries doing innovative things to help their communities

A Young student assesses the Programme for International Student Assessment (PISA)

UN condemns Syrian ‘war on children’ as up to 30 reportedly killed in clashes

Smart devices must come with trust already installed

Reusable packaging: 6 benefits beyond sustainability

Commission: Gifts of €6 billion and free trainees to ‘help’ poor employers

Air pollution could be responsible for 1 in 7 new cases of diabetes

Mergers: Commission opens in-depth investigation into PKN Orlen’s proposed acquisition of Lotos

Community Manager – 1289

Alarming level of reprisals against activists, human rights defenders, and victims – new UN report

How to turn Africa’s manufacturing sector into a high-tech powerhouse

5 lessons for the future success of virtual and augmented reality

What makes a great CEO? The people they surround themselves with

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s